TNFRSF17 and Miyoshi myopathy: Recent years, chimeric antigen receptor T-cell (CAR-T) therapies, especially those targeting B-cell maturation antigen (BCMA), a cell surface glycoprotein primarily expressed by plasma cells and some mature B cells, have shown remarkable efficacy in patients with relapsed or refractory MM (R/R MM) (8–11).